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Abstract
OBJECTIVE:  Endostatin is an anti-angiogenic agent that blocks matrix-metalloproteinase-2 and
inhibits endothelial cell proliferation. Currently, endostatin is available through recombinant
technology, which limits its broader use. In this study, a synthetic endostatin fragment (EF) was
analyzed to determine its anti-angiogenic properties when locally delivered by controlled-release
polymers and to establish its effect as a treatment for experimental gliomas.
METHODS:  Cytotoxicity of EF against 9L gliosarcoma and F98 glioma was determined in vitro.
EF was loaded into polyanhydride-poly-(bis-[carboxyphenoxy-propane]-sebacic-acid) (pCPP:SA)
polymers at increasing concentrations. Pharmacokinetics of the EF/polymer formulations were
defined in vitro. Anti-angiogenic properties of the EF/polymer formulations were evaluated in the
rat-cornea micropocket assay. Toxicity and efficacy of locally delivered EF polymers either alone
or combined with systemic bischloroethylnitrosourea (carmustine) were determined in rats
intracranially challenged with 9L gliosarcoma.
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RESULTS:  EF showed scarce cytotoxicity against 9L and F98 in vitro. EF/pCPP:SA formulations
showed sustained release by day 19. Mean corneal angiogenesis index 20 days after tumor
implantation was 4.5 ± 0.7 for corneas implanted with 40% EF/pCPP:SA compared with controls
(8.5 ± 1.3, P = 0.02). Intracranial efficacy studies showed that EF polymers alone did not prolong
animal survival. Combination of 40% EF/pCPP:SA polymers with systemic
bischloroethylnitrosourea (carmustine) prolonged survival (median survival of 44 d, P = 0.001) and
generated 33% long-term survivors.
CONCLUSION:  Controlled-release polymers can effectively deliver a biologically active EF in a
sustained fashion. EF inhibits angiogenesis in vitro and in vivo, and even though EF does not prolong
survival as a single agent, it exhibits a synergistic effect when combined with systemic
bischloroethylnitrosourea (carmustine) in the intracranial 9L gliosarcoma model.
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Angiogenesis is an essential mechanism tumor progression and increasing evidence validates
the role of specific inhibitors of this process as efficient antitumor agents (1,14). Endostatin,
a protein derived from collagen XVIII, has been shown to inhibit endothelial cell proliferation
(11), angiogenesis (1,14,34), tumor growth (35), and metastases (33). The cellular mechanisms
by which endostatin exerts its anti-angiogenic activity have not been completely elucidated
but include the inhibition of matrix-metalloproteinases (24) and arrest of endothelial and tumor
cells in the G1 phase with induction of apoptosis seen in some tumor lines (10), among others
(41,48).
Malignant gliomas constitutively express pro-angiogenic factors involved in several pathways
of neovascularization and exhibit marked dependence on angiogenesis for growth (27).
Endostatin has proven to be beneficial as an anti-angiogenic agent in experimental gliomas
(22,40,42,48), specifically decreasing tumor size and vascularization without development of
resistance or toxicity; however, endostatin has not been proven to prolong the survival of
animals challenged intracranially with malignant gliomas when used locally as single therapy
in an animal model (7). Currently, recombinant human endostatin is produced in limited
amounts because of high production costs, which limits the availability of the protein. The
endostatin obtained after recombinant synthesis encompasses 184aa, which makes it vulnerable
to denaturation when placed in solution and limits its stability (8).
Our group has previously demonstrated that the antiangiogenic effects of endostatin are
retained by fragments of the parent molecule (8,9). Fragments corresponding to sequences 6
to 49 and 134 to 178 have been isolated, characterized by circular dichroism spectroscopy and
nuclear magnetic resonance spectroscopy, and evaluated for anti-angiogenic activity in vitro
by using human umbilical vein endothelial cells for proliferation assays and Boyden chamber
migration analysis. The anti-angiogenic activity of the 6 to 49 endostatin fragment (EF) has
also been tested in vivo using the Matrigel assay in C57/b16 female mice (8,9). Furthermore,
EF 6 to 49 has been shown to have better solubility and increased stability when compared
with full-length endostatin.
Local delivery of anti-angiogenic agents has been advantageous in experimental models of
malignant gliomas (22,40,45,50). Local delivery of drugs at the tumor bed allows bypass of
the blood-brain barrier and results in higher concentrations in the targeted location while
minimizing undesired systemic effects (25,26). Furthermore, polymeric formulations of
chemotherapeutic agents have regulatory approval for clinical application (6,31,53), and the
combination of this therapeutic strategy with localized anti-angiogenic drug delivery could
potentially result in enhanced antitumor responses because of a synergistic effect. Indeed,
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previous work by our group and others demonstrated the benefit of combining locally delivered
anti-angiogenic agents such as the tetracycline derivative minocycline with chemotherapeutic
agents such as bischloroethylnitrosourea (BCNU, carmustine). This combination prolonged
survival in animals challenged with intracranial 9L gliosarcoma (15,52). Furthermore, the
combination of endostatin with a protein kinase Cα DNA enzyme (an inductor of apoptosis)
was successful in prolonging survival of rats with intracranial malignant glioma (47). This
strategy has also been successful in preclinical studies when a combination of thalidomide (an
anti-angiogenic agent) and either carmustine or temozolomide has been administered and is
currently undergoing further clinical testing (3,13).
In the present study, we hypothesized that controlled-release polymers loaded with EF were
capable of delivering bioactive concentrations of the fragment and would be effective to treat
animals challenged intracranially with 9L gliosarcoma either alone or combined with systemic
chemotherapy.
MATERIALS AND METHODS
Polymer Preparation
Polyanhydride poly (bis-[carboxyphenoxy-propane]-sebacic-acid) polymer (pCPP:SA) 20:80,
by weight, was loaded with synthesized EF at 1%, 10%, 20%, 30%, and 40% concentrations
(w:w), as previously described (16,51). pCPP:SA and 6 to 49 EF were dissolved in 0.5 ml of
methylene chloride (Fisher Chemicals, Fair Lawn, NJ) and placed in a vacuum desiccator for
2 hours. The resultant polymer mixture was pressed into 10 mg wafers and stored at −20°C.
BCNU
BCNU was purchased as BiCNU for injection (Bristol-Myers Squibb Company, Princeton,
NJ) and reconstituted as instructed by the manufacturer. Preparations were administered
intraperitoneally (IP) at a dose of 10 mg/kg. BCNU was selected as the systemic agent for
combined therapy to compare the effects of this treatment with those previously obtained with
the combination of minocycline and BCNU (15).
In vitro Pharmacokinetics
Release kinetics were determined by using the bicinchoninic acid assay (Pierce, Chemical Co.,
Rockford, IL). Triplicate samples of pCPP:SA polymers (10 mg wafers) loaded with 6 to 49
EF at concentrations of 10%, 20%, and 40% were suspended in separate glass vials each
containing 1 ml of phosphate-buffered saline at 37°C, following the methods previously
described by Tamargo et al. for in vitro pharmacokinetic analysis of controlled-release
polymers (51). Polymers were sequentially transferred to fresh 1 ml aliquots of phosphate-
buffered saline at several time points up to 432 hours (19 d). The amount of EF was determined
spectrophotometrically by comparison with a standard absorbance curve.
In vitro Cytotoxicity of 6-49aa EF in 9L Gliosarcoma and F98 Glioma Cells
Cytotoxicity of the EF was evaluated in vitro against 9L and F98 cells with the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay (46). 9L and F98 cells were
plated in a 96-well plate (3500 cells/well) and incubated for 24 hours at 37°C, with a total
volume of 100 μl/well. EF was given at concentrations of 1, 10, 25, 50, and 100 μg/ml, and
percentages of cell viability were determined. Absorbance was measured with an enzyme-
linked immunoadsorbent assay plate reader (Beckman Coulter, model AD 340, Fullerton, CA)
at 270 nm.
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Toxicity of pCPP:SA/Endostatin Fragment Polymer in Fischer 344 Rats
Animals (n = 18) were intracranially implanted with 10 mg wafers of empty pCPP:SA and 5%,
10%, 20%, and 30% 6 to 49 EF-loaded pCPP:SA polymers. Rats were evaluated and weighed
preoperatively daily for 2 weeks, biweekly for 3 weeks, and weekly for 6 weeks to determine
signs of local and systemic toxicity. Animals were killed at 120 days, and their organs were
harvested, fixed, and processed for histopathological analysis.
Rat Cornea Micropocket Angiogenesis Assay
Fischer 344 rats were used for this experiment (n = 8 rats, n = 16 corneas). The corneal
micropocket assay was used in this study as previously described (38,43). Loaded polymers
were implanted in the right eye of the animals, and empty polymers were implanted in the left
eye; therefore, every animal had its own control. Animals were anesthetized as previously
described (50), and topical anesthesia was administered with Proparacaine-HCL, (0.5% Bausch
and Lomb Pharmaceuticals Inc, Tampa, FL). Under direct vision with a Zeiss operating
microscope with use of a 14G needle and a #11 blade, a 2 × 2 mm pocket was made by blunt
dissection of the corneal epithelium with a 2 mm spatula not penetrating the anterior chamber.
A fresh tumor piece of 9L gliosarcoma grown in the flank of a carrier animal (rat) was harvested
and inserted followed by the polymer implant. Angiogenesis was measured with a Zeiss slit
lamp (Carl Zeiss, Thornwood , NY) at 0, 5, 8, 12, 15, and 21 days after implantation. An
angiogenesis index (AI), previously described (50), was used to evaluate the corneas. The AI
was obtained by multiplying the vessel length from the sclerocorneal junction to the leading
edge of the new vessel by the vessel number represented in a four-level scale in which 0 = 0
vessels, 1 = 1 to 10 vessels, 2 = more than10 vessels loosely packed with the iris adequately
visible through the gaps, and 3 = more than 10 vessels tightly packed without visualization of
the iris.
Efficacy of EF/pCPP:SA Polymers in Rat 9L Gliosarcoma Model
Experimental design—Female Fischer 344 rats (n = 64, 8 per group) were housed in
standard animal facilities, given free access to Baltimore city water and rodent chow, and
randomized into eight experimental groups (Table 1). Animals in group 1 (controls) received
9L intracranial tumor only. Animals in group 2 received EF/pCPP:SA polymer only
simultaneously with the tumor implant (day 0), whereas animals in group 3 received EF/
pCPP:SA polymer only on day 3. Group 4 received EF/pCPP:SA polymer on day 5 only, and
group 5 received IP BCNU only on day 5. Animals in group 6 received combination of EF/
pCPP:SA polymers on day 3 and IP BCNU on day 5. Animals in group 7 received combination
of EF/pCPP:SA polymer on day 5 and IP BCNU on day 5, whereas animals in group 8 received
the combination EF/pCPP:SA polymer on day 0 and IP BCNU on day 5. All implanted
polymers were 40% loaded with EF by weight.
Surgical procedure
Anesthesia was administered as previously described (50). The heads were shaved and
prepared, and tumor and polymers were implanted (51). A midline scalp incision was made,
the galea was dissected laterally, and a 3 mm burr hole was made over the left parietal bone
with its center 5 mm posterior to the coronal suture and 3 mm lateral to the sagittal suture. A
small section of parietal cortex was removed with suction, and a 40% EF/pCPP:SA polymer
was placed into the brain parenchyma approximately 1 mm below the dura. After ensuring
hemostasis, the skin was closed with surgical staples, and animals were returned to their cage
and closely monitored daily. Median survival and long-term survivors were considered as end
points. The Animal Care and Use Committee of the Johns Hopkins University approved all
experimental protocols.
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Statistical analysis
Statistical analysis was performed with SPSS version 8.0 for windows (Chicago, IL).
Cytotoxicity determined in vitro by the MTT assay and angiogenic indexes calculated for the
cornea angiogenesis assay were analyzed with one-way analysis of variance, followed by a
Student-Newman-Keuls test, and values are expressed as mean ± standard error of the mean
(SEM). Kaplan-Meier curves for the efficacy studies were analyzed on the basis of survival
algorithms, and significance was determined by the log-rank and Kruskal-Wallis tests. All
experimental groups were analyzed by comparing their median survival with the median
survival of the control group. Further analysis was performed by comparing the median survival
of the groups treated with combination therapies with the survival of the group treated with
BCNU alone, using the same statistical methodology. A probability value of less than 0.05 was
considered significant for all tests.
RESULTS
In vitro Pharmacokinetics
The release rate of the EF from pCPP:SA polymers 10, 20, and 40% loaded (w:w) was measured
in vitro over a 19 day period. During this time, 10% loaded polymers released 12.8 ± 0.004%
of the loaded EF (128 ± 0.04 μg), 20% polymers released 7.2 ± 0.005% (144 ± 0.1 μg), and
40% polymers released 3.8 ± 0.0007% (152 ± 0.28 μg) (Fig. 1). Taking into consideration the
total amount of fragment released and the fact that biodegradable polymers theoretically
improve their degradation kinetics in vivo, the 40% loaded polymer was chosen for subsequent
experiments.
In vitro Cytotoxicity in 9L Gliosarcoma and F98 Glioma
Cytotoxicity of the EF on 9L and F98 cells in vitro was determined with the MTT assay.
Treatment with increasing concentrations of the EF showed growth inhibition of 9L
gliosarcoma cells at all concentrations tested, including 1 μg/ml (lowest concentration) after 3
days of exposure (P = 0.01); treatment with 100, 50, 25, and 10 μg/ml decreased the percentage
of cell viability to 71 ± 3%, 81 ± 2.4%, 91 ± 3%, and 91 ± 4%, respectively, compared with
control (Fig. 2A). Similarly, treatment of F98 glioma cells with increasing concentrations of
the EF showed a decrease in cell viability at concentrations of 100, 50, and 25 μg/ml, generating
65 ± 1.7%, 78 ± 2%, and 81 ± 2% cell viability, respectively, after 3 days of exposure (P <
0.001); treatment of F98 cells with 10 and 1 μg/ml (lowest concentrations) did not significantly
decrease the percentage of cell viability when compared with control (Fig. 2B).
In vivo Toxicity in Fischer 344 Rats
Toxicity of the EF was evaluated by following neurological status and weight gain in animals
implanted intracranially with 10 mg pCPP:SA polymer alone and pCPP:SA polymers loaded
with EF 5%, 10%, 20%, and 30% (w:w). Animals in all groups continued to gain weight up to
the day of euthanasia (120) without local or systemic toxicity (Fig. 3). After euthanasia, full
necropsies were performed in all the animals. Analysis of histological specimens confirmed
the absence of focal and systemic toxicity.
Rat Cornea Micropocket Angiogenesis Assay
The anti-angiogenic activity of 40% EF/pCPP:SA polymers was determined in the corneas of
Fischer 344 rats implanted with 9L gliosarcoma. Angiogenesis was measured at 5, 8, 12, 15,
and 20 days. At days 12, 15, and 20, animals implanted with 40% EF/pCPP:SA polymers had
mean AI of 2.9 ± 0.58 compared with 4.6 ± 0.52 in the control at day 12 (P = 0.038), 4.0 ± 0.7
compared with 6.0 ± 0.64 in the control at day 15 (P = 0.044), and 4.5 ± 0.7 compared with
8.5 ± 1.3 at day 20 (P = 0.02) (Fig. 4A). Mean AI was not significant at both day 8 (1.5 ± 0.48
Pradilla et al. Page 5
Neurosurgery. Author manuscript; available in PMC 2006 November 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
in the EF group compared with 2.1 ± 0.43 in the control, P = 0.310) and day 5 (0 compared
with 0.2 ± 0.2 in the control, P = 0.334) (Fig. 4B)
Efficacy of Endostatin Fragment/pCPP:SA Polymers in the Rat 9L Gliosarcoma Model
Animals treated with single agents, either 40% EF/ pCPP:SA polymers implanted alone on
day 0 (group 2), day 3 (group 3), or day 5 (group 4) and systemic BCNU administered on day
5 (group 5) had median survivals of 14, 12, 12, and 26 days, respectively (no statistical
significance was found with EF polymers alone compared to controls). Animals treated with
a combination of locally delivered EF and systemic BCNU had significantly higher survival
rates when compared with either treatment alone and controls and produced long-term
survivors (Fig. 6). Whereas combination therapy with intracranial 40% EF/pCPP:SA polymer
on day 0 and systemic BCNU (group 8) significantly improved animal survival (median
survival of 44 d, P < 0.001) and generated 33% long-term survivors (survival >120 d), animals
in the control group (9L tumor no treatment, group 1) had a median survival of 11 days.
Similarly, treatment with a combination of 40% EF/pCPP:SA polymer on day 3 and systemic
BCNU on day 5 (group 6) had a median survival of 28 days (P < 0.001) and generated 12.5%
long-term survivors, and animals treated with 40% EF/pCPP:SA polymer on day 5 and
systemic BCNU on day 5 (group 7) resulted in a median survival of 24 days (P < 0.001) and
generated 12.5% long-term survivors.
To further evaluate the benefit of combined therapy with EF and BCNU, the survival of group
5 (BCNU alone) was compared with that of groups 6, 7, and 8 combination groups. This
analysis showed that treatment with EF day 0 + BCNU day 5 and EF day 3 + BCNU day 5
significantly prolonged animal survival when compared with BCNU alone (P = 0.001 and P
= .0368, respectively). The survival of animals treated with EF day 5 + BCNU day 5, however,
was not significantly greater than the survival of animals treated with BCNU alone (P = 0.765).
DISCUSSION
In this study, a fragment of human endostatin corresponding to sequences 6 to 49 was
synthesized and incorporated into controlled-release polymers to determine the anti-angiogenic
and antitumor activity of the polymer formulations in an experimental model of malignant
glioma. We found that the EF was released in a controlled fashion from pCPP:SA polymers
in vitro and that it maintained its anti-angiogenic potential in the rat cornea micropocket assay.
Furthermore, EF-loaded polymers implanted intracranially did not generate local or systemic
toxicity. Treatment with EF polymers alone showed a trend toward prolonged animal survival,
particularly when polymers where implanted on day 0 (simultaneously with the tumor implant)
but did not reach statistical significance. When EF polymers were used in combination with
systemic BCNU, however, a statistically significant synergistic effect was obtained that
prolonged the survival of animals challenged intracranially with 9L gliosarcoma and generated
long-term survivors.
Vascularization of malignant gliomas requires increased angiogenesis, which depends greatly
on endothelial cell proliferation (21). Under physiological conditions, angiogenesis is
stringently regulated by a delicate balance between enhancing and inhibitory modulators.
Enhancers of angiogenesis such as vascular endothelial growth factor (VEGF) , basic fibroblast
growth factor, and hepatocyte growth factor/scatter factor among others are counterbalanced
by inhibitors of angiogenesis such as endostatin (21). Angiogenesis inhibitors modulate the
interactions between endothelial cells and extracellular matrix components such as collagen
and integrins (i.e., αvβ-3) (4), which are required for new vessel formation.
We have previously tested the anti-angiogenic activity of this EF using Matrigel assays in vitro
as well as in vivo (9), and in the present study, we confirmed this activity against an
Pradilla et al. Page 6
Neurosurgery. Author manuscript; available in PMC 2006 November 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
experimental glioma using the rat cornea-micropocket assay. Angiogenesis in the Matrigel
assays previously performed was induced through stimulation with VEGF and fibroblast
growth factor and the angiogenic stimuli in the rat cornea micropocket assay was provided by
the implanted tumor (9L). Angiogenesis induced by 9L in particular has been shown to be
largely dependent on the presence VEGF (36) and fibroblast growth factor (29) among other
factors. Therefore, we believe that the anti-angiogenic activity of this EF must be maintained
when the fragment is administered locally to the brain.
Endostatin is an endogenous antiangiogenic protein activated by proteolytic processing (12)
that inhibits endothelial cell proliferation, migration, invasion, and microvessel formation (1).
Its inhibitory activity involves binding to the α5β1 receptor (49) and to glypican-1/4 among
other mechanisms (23). Endostatin reduces endothelial cell survival, motility, and invasion
possibly through blockade of VEGF/VEGF-receptor signaling (19), inhibition of
metalloproteinases (24), and downregulation of c-myc and cyclin-D1 (20,44). The efficacy of
endostatin as an anti-angiogenic/antitumor agent has been extensively evaluated in animal
models (18,39); however, its effect in survival of animals challenged with malignant gliomas
has shown variable results (7,33,40,48). Currently, endostatin is available through recombinant
technology that generates the 184-amino acid parent molecule. To improve the solubility and
stability of endostatin and to facilitate its synthesis the 6-49aa fragment of endostatin was
synthesized by our group and tested to establish its pharmacological properties and to determine
its anti-angiogenic and antitumor activity (8,9,30). When compared with full-length human
endostatin and with other fragments of the parent molecule, 6 to 49 EF was found to be fully
biologically active and in some instances, showed even greater potency and efficacy than full-
length human endostatin itself (8).
To enhance the potential activity of the 6 to 49 EF, adequate bioactive concentrations must
reach the tumor site. Because of the nature of the blood-brain barrier, penetration to the tumor
site by systemic administration of the fragment is likely to be inadequate. Therefore, a
biodegradable polymer system, currently approved by the Food and Drug Administration for
direct delivery of BCNU to clinically treat malignant glioma, was used to determine the
pharmacokinetic properties of the locally delivered EF. The pCPP:SA polymer system allows
diffusion of the fragment toward the interstitium and further release through biodegradation
of the polymer matrix.
Successful preclinical studies on anti-angiogenic agents have resulted in clinical trials that
tested diverse strategies of anti-angiogenesis to treat several malignancies (2). Among these
strategies, monoclonal antibodies against VEGF-receptor (5), EGF-receptor, and αvβ3, as well
as specific inhibitors of pro-angiogenic factors such as matrix metalloproteinase inhibitors and
integrin blockers (2) have been used with varied results. In the present study, although the anti-
angiogenic activity of endostatin was not sufficient to significantly prolong animal survival
when used as a single agent, the combination of locally delivered endostatin and systemic
chemotherapy was synergistic and greatly prolonged survival.
The response to endostatin observed in vitro, as well as the anti-angiogenic activity seen in the
corneal assays, contrasts the limited response to monotherapy with the EF polymers in vivo.
This phenomenon, however, has been observed with several antiangiogenic therapies in a
variety of tumors including gliomas in experimental and clinical scenarios (17,28,32). Our
findings and those of other groups suggests that angiogenesis inhibitors behave primarily as
cytostatic agents that stabilize the disease, and therefore anti-angiogenesis alone is unlikely to
significantly decrease glioma growth in vivo. Nevertheless, the temporal stasis in tumor growth
provided by anti-angiogenic agents is likely to enhance the activity of conventional cytotoxic
agents with proven anti-glioma activity.
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On the basis of the results of our toxicity study, an increase in the dose of EF delivered can be
pursued to enhance its efficacy in vivo. This can be achieved by either increasing the loading
concentration of EF in the polymers, implanting more polymers (limited by the size of the rat
brain), or selecting an alternative delivery system such as convection-enhanced delivery.
Experience gathered in preclinical studies by our group and others has shown that combined
therapy with cytotoxic alkylating agents such as BCNU and locally delivered anti-angiogenic
agents such as endostatin is an effective strategy for treating experimental malignant gliomas
(15,37,52). This strategy is further supported by the results obtained in this study, which show
that combination of systemic BCNU and locally delivered EF provides a synergistic and
complementary approach that generates long-term survivors.
In conclusion, this synthetic EF demonstrates strong anti-angiogenic properties; it is not
efficacious for treatment of intracranial experimental gliomas when used alone, but has a
synergistic effect when combined with BCNU for treatment of experimental gliomas. When
incorporated into controlled-release polymers, the fragment maintained its biological activity
and exhibited no signs of local or systemic toxicity. Further studies are required to evaluate
the potential for synergistic activity of this EF when administered simultaneously with other
anti-neoplastic agents and radiotherapy to establish its potential translation into clinical
scenarios.
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FIGURE 1.
Pharmacokinetics. The release rate of EF from pCPP:SA 10, 20, and 40% (w:w) measured
over 19 days in vitro. Sustained release of EF was observed with all polymer formulations.
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FIGURE 2.
Cytotoxicity of the endostatin fragment on 9L and F98 cells in vitro was determined with the
MTT assay. (A) 9L gliosarcoma. Significant growth inhibition of 9L was achieved at all
concentrations tested. (B) F98 glioma. EF showed significant decrease in F98 cell viability at
100, 50, and 25 μg/ml but not at 10 and 1 μg/ml when compared with control.
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FIGURE 3.
Toxicity-weight gain correlation. Animals were treated with different formulations of EF
polymers. All animals showed weight gain up to the day of euthanasia without local or systemic
toxicity; no differences were found between groups.
Pradilla et al. Page 14
Neurosurgery. Author manuscript; available in PMC 2006 November 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIGURE 4.
Corneal angiogenesis: corneal angiogenesis index. The anti-angiogenic activity of 40% EF/
pCPP:SA polymers was determined in corneas of rats implanted with 9L. Corneas treated with
EF/pCPP:SA showed significantly lower AI values compared with control corneas. (A)
Progression of angiogenesis and tumor size in a cornea implanted with 9L and treated with
empty polymer. Arrows indicate the periphery of the tumor. (B) Progression of angiogenesis
and tumor size in a cornea implanted with 9L and treated with 40% EF/pCPP:SA. P, polymer
implant; T, 9L tumor piece.
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FIGURE 5.
Kaplan-Meier animal survival curve. Efficacy of 40% EF/pCPP:SA polymers was tested in
the rat 9L model. Animals treated with a combination of locally delivered EF and systemic
BCNU had significantly higher survival rates when compared with either treatment alone and
controls and produced long-term survivors.
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FIGURE 6.
Coronal section from the brain of a rat implanted with 9L and treated with EF/pCPP:SA on
day 0 and systemic BCNU on day 5 (H&E). A ×4 magnification (A) shows the EF/polymer
(P) matrix in its biodegradation process, and the 9L gliosarcoma tumor (T) surrounding the
implant. Higher magnification is observed in B and C.
Pradilla et al. Page 17
Neurosurgery. Author manuscript; available in PMC 2006 November 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Pradilla et al. Page 18
TA
B
LE
 1
Ex
pe
rim
en
ta
l g
ro
up
s:
 in
tra
cr
an
ia
l e
ff
ic
ac
y 
st
ud
y 
in
 ra
ts
a
G
ro
up
T
re
at
m
en
t g
ro
up
s
M
ed
ia
n 
su
rv
iv
al
M
ea
n 
su
rv
iv
al
R
an
ge
1
(C
on
tro
l) 
9L
 in
tra
cr
an
ia
l t
um
or
 o
nl
y
11
12
11
–1
3
2
En
do
st
at
in
 fr
ag
m
en
t/p
ol
ym
er
 (D
ay
 0
)
14
15
11
–2
1
3
En
do
st
at
in
 fr
ag
m
en
t/p
ol
ym
er
 (D
ay
 3
)
12
13
11
–1
8
4
En
do
st
at
in
 fr
ag
m
en
t/p
ol
ym
er
 (D
ay
 5
)
12
13
11
–1
8
5
IP
 B
C
N
U
 (D
ay
 5
)
26
26
20
–3
1
6
En
do
st
at
in
 fr
ag
m
en
t/p
ol
ym
er
 (D
ay
 3
) +
 IP
 B
C
N
U
 (D
ay
 5
)
28
40
27
–1
00
7
En
do
st
at
in
 fr
ag
m
en
t/p
ol
ym
er
 (D
ay
 5
) +
 IP
 B
C
N
U
 (D
ay
 5
)
24
32
11
–1
00
8
En
do
st
at
in
 fr
ag
m
en
t/p
ol
ym
er
 (D
ay
 0
) +
 IP
 B
C
N
U
 (D
ay
 5
)
44
70
31
–1
20
a I
P,
 in
tra
pe
rit
on
ea
lly
; B
C
N
U
, b
is
ch
lo
ro
et
hy
ln
itr
os
ou
re
a 
(c
ar
m
us
tin
e)
.
Neurosurgery. Author manuscript; available in PMC 2006 November 7.
